KR880011148A - 레티노이드와 같은 작용성을 가지며 이종방향족 그룹과 이종이환식 그룹을 갖는 치환된 아세틸렌 - Google Patents

레티노이드와 같은 작용성을 가지며 이종방향족 그룹과 이종이환식 그룹을 갖는 치환된 아세틸렌 Download PDF

Info

Publication number
KR880011148A
KR880011148A KR1019880002880A KR880002880A KR880011148A KR 880011148 A KR880011148 A KR 880011148A KR 1019880002880 A KR1019880002880 A KR 1019880002880A KR 880002880 A KR880002880 A KR 880002880A KR 880011148 A KR880011148 A KR 880011148A
Authority
KR
South Korea
Prior art keywords
compound
lower alkyl
carbon atoms
pharmaceutically acceptable
saturated aliphatic
Prior art date
Application number
KR1019880002880A
Other languages
English (en)
Other versions
KR960014357B1 (en
Inventor
에이.에스.챤드라라트나 로산타
Original Assignee
제임스 엠.케나지
알러겐, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제임스 엠.케나지, 알러겐, 인크. filed Critical 제임스 엠.케나지
Publication of KR880011148A publication Critical patent/KR880011148A/ko
Application granted granted Critical
Publication of KR960014357B1 publication Critical patent/KR960014357B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Dental Preparations (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

내용 없음

Description

레티노이드와 같은 작용성을 가지며 이종방향족 그룹과 이종이환식 그룹을 갖는 치환된 아세틸렌
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (20)

  1. X가 S, O 또는 R′가 수소 또는 저급알킬인 NR′이며 ; R이 수소이거나 저급알킬이며 ; A가 피리딜, 티에틸, 푸릴, 피리다지닐, 피리미디닐, 또는 피라지닐이며 ; n이 0-5이고 ; B는 H이거나 B가 -COOH, 이것의 제약학적으로 허용되는 염, 탄소원자수가 10개 또는 그 이하의 포화된 지방족 알코올이나 5 내지 10개 탄소원자수의 환식 또는 포화된 지방족 환식 알코올의 또는 페놀의 에스테르 또는 탄소수가 10개 또는 그이하의 포화된 지방족 알코올의 아미드나 일-또는 이-치환된 아미드, 또는 이것의 5 내지 10개 탄소원자수의 환식 또는 포화된 지방족 환식기, 또는 B가 -CH2OH이거나 탄소원자수가 10개 또는 그 이하의 포화된 지방족 산의 저급알킬 에테르나 에스테르 또는 5 내지 10개 탄소원자수의 환식 또는 포화된 지방족 환식산이나 벤조산의 저급알킬 에테르나 에스테르, 또는 B가 -CHO이거나 이것의 저급알킬 아세탈 유도체, 또는 m이 0-4이고 R1이 -(CH2)mCH3인 -COR1이거나 이것의 저급알킬케탈 유도체인 다음 일반식의 화합물 또는 제약학적으로 허용되는 이것의 염.
  2. X가 S이며, R이 수소이고, A가 피리딜 또는 티에닐이며, n이 0,1 또는 2인 제1항의 화합물.
  3. A가 피리딜이며 B가 -COOH 또는 제약학적으로 허용되는 이것의 염, 에스테르 또는 아미드인 제2항의 화합물.
  4. 에틸 6-[2-(4,4-디메틸티오크로만-6-일)에티닐]니코티노에이트 또는 제약학적으로 허용되는 이것의 염인 제3항의 화합물.
  5. 6-[2-(4,4-디메틸티오크로만-6-일)에티닐]니코틴산 또는 제약학적으로 허용되는 이것의 염인 제3항의 화합물.
  6. B가 수소인 제2항의 화합물.
  7. B가 -CH2OH 또는 이것의 에테르나 에스테르 유도체인 제2항의 화합물.
  8. B가 -CHO 또는 이것의 아세탈 유도체인 제2항의 화합물.
  9. B가 R2가 -(CH2)mCH이며 m이 0-4인 -COR2이거나 이것의 케탈유도체인 제2항의 화합물.
  10. X가 O, R이 수소, A가 피리딜 또는 티에닐이며 n이 0,1 또는 2인 제1항의 화합물.
  11. A가 피리딜, B가 -COOH 또는 제약학적으로 허용되는 이것의 염, 에스테르 또는 아미드인 제10항의 화합물.
  12. 6-[2-(4,4-디메틸크로만-6-일)에티닐]니코틴산 또는 제약학적으로 허용되는 이것의 염인 제11항의 화합물.
  13. 에틸 6-[2-(4,4-디메틸크로만-6-일)에티닐]니코티노에이트 또는 제약학적으로 허용되는 이것의 염인 제11항의 화합물.
  14. B가 수소인 제10항의 화합물.
  15. B가 -CH2OH 또는 이것의 에테르 혹은 에스테르 유도체인 제10항의 화합물.
  16. B가 -CHO 또는 이것의 아세탈 유도체인 제10항의 화합물.
  17. B가 R2가 -(CH2)mCH3이며 0-4인 -COR2이거나 이것의 케탈 유도체인 제10항의 화합물.
  18. X가 S, O 또는 R′가 수소 또는 저급알킬인 NR′이며 ; R이 수소이거나 저급알킬이며 ; A가 피리딜, 티에틸, 푸릴, 피리다지닐, 피리미디닐, 또는 피라지닐이며 ; n이 0-5이고 ; B는 H이거나 B가 -COOH, 이것의 제약학적으로 허용되는 염, 탄소원자수가 10개 또는 그 이하의 포화된 지방족 알코올이나 5 내지 10개 탄소원자수의 환식 또는 포화된 지방족 환식 알코올의 또는 페놀의 에스테르 또는 탄소수가 10개 또는 그이하의 포화된 지방족 알코올의 아미드나 일 -또는 이-치환된 아미드, 또느 이것의 5 내지 10개 탄소 원자수의 환식 또는 포화된 지방족 산의 저급알킬 에테르나 에스테르 또는 5 내지 10개 탄소원자수의 환식 또는 포화된 지방족 환식산이나 벤조산의 저급알킬 에테르나 에스테르, 또는 B가 -CHO이거나 이것의 저급알킬 아세탈 유도체, 또는 m이 0-4이고 R1이 -(CH2)mCH3인 -COR1이거나 이것의 저급알킬케탈 유도체인 다음 일반식의 화합물 또는 제약학적으로 허용되는 이것의 염과 제약학적으로 허용되는 부형제로 이루어지는 제약학적 조성물.
  19. 포유동물에서 건선을 치료하기에 유용한 제18항에 따른 조성물.
  20. X가 S, O 또는 R′가 수소 또는 저급알킬인 NR′이며 ; R이 수소이거나 저급알킬이며 ; A가 피리딜, 티에틸, 푸릴, 피리다지닐, 피리미디닐, 또는 피라지닐이며 ; n이 0-5이고 ; B는 H이거나 B가 -COOH, 이것의 제약학적으로 허용되는 염, 탄소원자수가 10개 또는 그 이하의 포화된 지방족 알코올이나 5 내지 10개 탄소원자수의 환식 또는 포화된 지방족 환식 알코올의 또는 페놀의 에스테르 또는 탄소수가 10개 또는 그이하의 포화된 지방족 알코올의 아미드나 일-또는-이-치환된 아미드, 또는 이것의 5 내지 10개 탄소원자수의 환식 또는 포화된 지방족 환식기, 또는 B가 -CH2OH이거나 탄소원자수가 10개 또는 그 이하의 포화된 지방족 산의 저급알킬 에테르나 에스테르 또는 5 내지 10개 탄소원자수의 환식 또는 포화된 지방족 환식산이나 벤조산의 저급알킬에테르나 에스테르, 또는 B가 -CHO이거나 이것의 저급알킬 아세탈 유도체, 또는 m이 0-4이고 R1이 -(CH2)mCH3인 -COR1이거나 이것의 저급알킬케탈 유도체인 다음 일반식의 화합물의 치료에 효과적인 양 또는 제약학적으로 허용되는 이것의 염과 제약학적으로 허용되는 부형제를 함께 또는 단독으로 투여하는 것으로 이루어지는, 포유동물에서 건선을 치효하는 방법.
    ㅛ
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR88002880A 1987-03-20 1988-03-18 Heterobicyclic groups having retinoid like activity KR960014357B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2827987A 1987-03-20 1987-03-20
US028,279 1987-03-20

Publications (2)

Publication Number Publication Date
KR880011148A true KR880011148A (ko) 1988-10-26
KR960014357B1 KR960014357B1 (en) 1996-10-15

Family

ID=21842553

Family Applications (1)

Application Number Title Priority Date Filing Date
KR88002880A KR960014357B1 (en) 1987-03-20 1988-03-18 Heterobicyclic groups having retinoid like activity

Country Status (23)

Country Link
EP (1) EP0284288B1 (ko)
JP (2) JPH085874B2 (ko)
KR (1) KR960014357B1 (ko)
CN (1) CN1026789C (ko)
AT (1) ATE76641T1 (ko)
AU (1) AU613346B2 (ko)
CA (1) CA1305480C (ko)
DE (2) DE3871414D1 (ko)
DK (1) DK175081B1 (ko)
ES (1) ES2034196T3 (ko)
FI (1) FI92398C (ko)
GR (1) GR3005243T3 (ko)
HK (1) HK5794A (ko)
HU (1) HU204818B (ko)
IE (1) IE60566B1 (ko)
IL (1) IL85787A (ko)
LU (1) LU90227I2 (ko)
MY (1) MY103237A (ko)
NO (1) NO169489C (ko)
NZ (1) NZ223948A (ko)
PH (1) PH27119A (ko)
PT (1) PT86975B (ko)
ZA (1) ZA881515B (ko)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149705A (en) * 1987-03-13 1992-09-22 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a tetralin group and having retinoid like activity
CA1305480C (en) * 1987-03-20 1992-07-21 Roshantha A.S. Chandraratna Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US5264578A (en) 1987-03-20 1993-11-23 Allergan, Inc. Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity
US5602130A (en) * 1987-03-20 1997-02-11 Allergan Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US5234926A (en) * 1987-03-20 1993-08-10 Allergan, Inc. Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US5248777A (en) * 1989-09-19 1993-09-28 Allergan, Inc. Process and intermediates for preparing compounds having a disubstituted acetylene moiety and retinoic acid-like biological activity
US5183827A (en) * 1989-09-19 1993-02-02 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US5272156A (en) * 1989-09-19 1993-12-21 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a 2-substituted 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US5045551A (en) * 1989-09-19 1991-09-03 Allergan, Inc. Acetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
US5399561A (en) * 1989-09-19 1995-03-21 Allergan, Inc. Acetylenes disubstituted with a phenyl or heteroaryl group and a 2-oxochromanyl, 2-oxothiochromanyl or 2-oxo-1,2,3,4-tetrahydro-quinolinyl group having retinoid-like biological activity
US5013744B1 (en) * 1989-12-29 1994-09-20 Allegran Inc Acetylenes disubstituted with a pyridinyl group and a substituted phenyl group having retinoid like activity
US5264456A (en) * 1989-12-29 1993-11-23 Allergan, Inc. Acetylenes disubstituted with a furyl group and a substituted phenyl group having retinoid like activity
US5202471A (en) * 1990-02-06 1993-04-13 Allergan, Inc. Alkyl, alkoxy and thioalkoxy substituted diphenyl acetylenes having retinoid like activity
CA2091763A1 (en) * 1990-10-09 1992-04-10 Roshantha A. S. Chandraratna Acetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydroquinolinyl group having retinoid-like activity
JP3062248B2 (ja) * 1991-02-13 2000-07-10 アラーガン、インコーポレイテッド レチノイド様生物学的活性を有する７位にフェニルエチニル置換基を有するクロマンおよびチオクロマン
US5134159A (en) * 1991-03-26 1992-07-28 Allergan, Inc. 7-chromanyl esters of phenols and benzoic acids having retinoid-like activity
WO1992017471A1 (en) * 1991-03-26 1992-10-15 Allergan, Inc. Chromans and thiochromans with heteroarylethynyl substituents at the 7-position having retinoid-like biological activity
EP0626955A1 (en) * 1992-02-11 1994-12-07 Allergan, Inc. Heteroaryl substituted phenylethenyl compounds having retinoid-like biological activity
US5962731A (en) * 1992-04-22 1999-10-05 Ligand Pharmaceuticals Incorporated Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
US5780676A (en) * 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
US7655699B1 (en) 1992-04-22 2010-02-02 Eisai Inc. Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
US5324840A (en) * 1992-06-11 1994-06-28 Allergan, Inc. Method of treatment with compounds having retinoid-like activity and reduced skin toxicity and lacking teratogenic effects
US6172115B1 (en) 1993-02-11 2001-01-09 Allergan Sales, Inc. Method for preventing onset of restenosis after angioplasty employing an RXR-specific retinoid
US5455265A (en) 1993-02-11 1995-10-03 Allergan, Inc. Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
US5399586A (en) * 1993-03-11 1995-03-21 Allergan, Inc. Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity
US5344959A (en) * 1993-05-18 1994-09-06 Allergan, Inc. Tetrahydronaphthyl and cyclopropyl substituted 1,3-butadienes having retinoid-like activity
US5475022A (en) * 1993-10-18 1995-12-12 Allergan, Inc. Phenyl or heteroaryl and tetrahydronaphthyl substituted diene compounds having retinoid like biological activity
US5451605A (en) * 1993-12-30 1995-09-19 Allergan, Inc. 1,2-epoxycyclohexanyl and bicyclic aromatic substituted ethyne compounds having retinoid-like biological activity
US5426118A (en) * 1993-12-30 1995-06-20 Allergan, Inc. [4-(1,2-epoxycyclohexanyl)but-3-en-1-ynyl]aromatic and heteroaromatic acids and derivatives having retinoid-like biological activity
US5470999A (en) * 1993-12-30 1995-11-28 Allergan, Inc. Cyclohexene and bicyclic aromatic substituted ethyne compounds having retinoid-like biological activity
US5498755A (en) * 1994-08-23 1996-03-12 Chandraratna; Roshantha A. Disubstituted aryl and heteroaryl imines having retinoid-like biological activity
US5618931A (en) * 1994-12-29 1997-04-08 Allergan Acetylenes disubstituted with a 5 substituted dihydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
US5648514A (en) 1994-12-29 1997-07-15 Allergan Substituted acetylenes having retinoid-like biological activity
US5534641A (en) * 1994-12-29 1996-07-09 Allergan Acetylenes disubstituted with 2-tetrahydropyranoxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
US5543534A (en) * 1994-12-29 1996-08-06 Allergan Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl groups having retinoid-like biological activity
US5556996A (en) * 1994-12-29 1996-09-17 Allergan Oxiranyls disubstituted with a phenyl group and a substituted chromanyl or tetrahydroquinolinyl group having retinoid like activity
US5599967A (en) * 1994-12-29 1997-02-04 Allergan Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl of heteroaryl group having retinoid-like biological activity
US5489584A (en) * 1994-12-29 1996-02-06 Allergan, Inc. Acetylenes disubstituted with a 5-amino or substituted 5-amino substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
CA2208844A1 (en) * 1994-12-29 1996-07-11 Alan T. Johnson Acetylenes disubstituted with a 5 or 8 substituted tetrahydronaphthyl or dihydronaphthyl group and with an aryl or heteroaryl groups having retinoid-like biological activity
US5618943A (en) * 1994-12-29 1997-04-08 Allergan Acetylenes disubstituted with a 5 OXO substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
US5514825A (en) * 1994-12-29 1996-05-07 Allergan, Inc. Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
US6025388A (en) * 1995-04-26 2000-02-15 Allergan Sales, Inc. Method for inhibiting gene expression promoted by AP1 protein with RARβ selective retinoids and method for treatment of diseases and conditions with such retinoids
US5616712A (en) * 1995-05-16 1997-04-01 Allergan Acetylenes disubstituted with a phenyl or heteroaryl group and a 2-thio-1,2,3,4-tetrahdroquinolinyl, 2-alkylthio-3,4-dihydroquinolinyl or 2-alkoxy-3,4-dihydroquinolinyl group having retinoid-like biological activity
US5675033A (en) * 1995-06-06 1997-10-07 Allergan 2,4-pentadienoic acid derivatives having retinoid-like biological activity
US5917082A (en) 1995-06-06 1999-06-29 Allergan Sales, Inc. 2,4-pentadienoic acid derivatives having retinoid-like biological activity
US6218128B1 (en) 1997-09-12 2001-04-17 Allergan Sales, Inc. Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities
US6008204A (en) 1995-09-01 1999-12-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5958954A (en) * 1995-09-01 1999-09-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5952345A (en) 1995-09-01 1999-09-14 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
AU7598596A (en) * 1995-11-01 1997-05-22 Allergan, Inc. Sulfides, sulfoxides and sulfones disubstituted with a tetrahydronaphthalenyl, chromanyl, thiochromanyl or tetrahydroquinolinyl and substituted phenyl or heteroaryl group, having retinoid-like biological activity
US5663357A (en) * 1995-11-22 1997-09-02 Allergan Substituted heteroarylamides having retinoid-like biological activity
US5675024A (en) 1995-11-22 1997-10-07 Allergan Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4,-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity
US5688957A (en) * 1995-12-29 1997-11-18 Allergan (3"-thioxacyclohex-1"-enyl)!-but-3'-ene-1'-ynyl!aryl and (3"-thioxacyclohex-1"-enyl)!-but-3'-ene-1'-ynyl!heteroaryl carboxylic acids and esters having retinoid-like biological activity
US5965606A (en) 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
US5773594A (en) 1996-06-21 1998-06-30 Allergan Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US6555690B2 (en) 1996-06-21 2003-04-29 Allergan, Inc. Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5741896A (en) * 1996-06-21 1998-04-21 Allergan O- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5763635A (en) 1996-06-21 1998-06-09 Allergan Tetrahydronaphthalene derivatives substituted in the 8 position with alkyhidene groups having retinoid and/or retinoid antagonist-like biological activity
US5723666A (en) * 1996-06-21 1998-03-03 Allergan Oxime substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5808124A (en) * 1996-06-21 1998-09-15 Allergan O- or S-substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5747542A (en) * 1996-06-21 1998-05-05 Allergan Oxo-substituted tetrahydronaphthalene derivatives having retinold and/or retinoid antagonist-like biological activity
JPH10158192A (ja) 1996-10-03 1998-06-16 Eisai Co Ltd 移植片対宿主疾患（ｇｖｈｄ）の治療および臓器移植時の移植片拒絶反応抑制のための医薬組成物
US5739338A (en) * 1996-11-05 1998-04-14 Allergan N-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity
US5728846A (en) * 1996-12-12 1998-03-17 Allergan Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives
US5760276A (en) * 1997-03-06 1998-06-02 Allergan Aryl-and heteroarylcyclohexenyl substituted alkenes having retinoid agonist, antagonist or inverse agonist type biological activity
US6037488A (en) 1997-04-19 2000-03-14 Allergan Sales, Inc. Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
CA2307613A1 (en) * 1997-10-22 1999-04-29 Eisai Co., Ltd. Retinoic acid agonist as a prophylactic and therapeutic agent for nephritis
ITMI20050357A1 (it) 2005-03-08 2006-09-09 Solmag S P A Procedimento di preparazione del tazarotene
US20100076037A1 (en) * 2006-11-02 2010-03-25 Chiang Lillian W Methods of Treating Neuropathic Pain with Agonists of PPAR-gamma
CN107176945B (zh) 2016-03-11 2021-06-08 中国科学院上海有机化学研究所 一种视黄酸类化合物、其制备方法、中间体及应用
CN106749210B (zh) * 2016-11-22 2019-08-09 斯芬克司药物研发（天津）股份有限公司 一种烟酸酯类化合物及其制备方法与应用
CN106854204B (zh) * 2016-11-22 2019-10-08 斯芬克司药物研发（天津）股份有限公司 一种烟酸脂化合物及其制备方法与应用
CN106749211B (zh) * 2016-11-22 2019-08-09 斯芬克司药物研发（天津）股份有限公司 一种烟酸酯及其制备方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE793865A (fr) * 1972-09-25 1973-07-10 Syntex Corp Composes d'acides xanthone-carboxyliques substitues par des groupes alcenyles et alcynyles
DE3434946A1 (de) * 1984-09-22 1986-04-03 Basf Ag, 6700 Ludwigshafen Diarylacetylene, ihre herstellung und verwendung
CA1305480C (en) * 1987-03-20 1992-07-21 Roshantha A.S. Chandraratna Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US5015661A (en) * 1988-08-09 1991-05-14 Hoffmann-La Roche Inc. Chromanes and their pharmaceutical compositions and methods

Also Published As

Publication number Publication date
NO169489C (no) 1992-07-01
MY103237A (en) 1993-05-29
HK5794A (en) 1994-01-28
DE3871414D1 (de) 1992-07-02
FI92398B (fi) 1994-07-29
PT86975A (pt) 1988-04-01
DE19775022I2 (de) 2000-03-09
NZ223948A (en) 1990-04-26
DK175081B1 (da) 2004-05-24
CA1305480C (en) 1992-07-21
EP0284288A1 (en) 1988-09-28
LU90227I2 (fr) 1998-05-13
JPH085874B2 (ja) 1996-01-24
KR960014357B1 (en) 1996-10-15
AU613346B2 (en) 1991-08-01
ES2034196T3 (es) 1993-04-01
JPH07324085A (ja) 1995-12-12
GR3005243T3 (ko) 1993-05-24
FI92398C (fi) 1994-11-10
NO881200L (no) 1988-09-21
CN1026789C (zh) 1994-11-30
NO881200D0 (no) 1988-03-18
DK143988D0 (da) 1988-03-16
AU1326888A (en) 1988-09-22
IL85787A0 (en) 1988-09-30
JPS63255277A (ja) 1988-10-21
IL85787A (en) 1992-06-21
HUT50332A (en) 1990-01-29
HU204818B (en) 1992-02-28
PH27119A (en) 1993-03-16
FI881315A0 (fi) 1988-03-18
IE880802L (en) 1988-09-20
ATE76641T1 (de) 1992-06-15
DK143988A (da) 1988-09-21
NO169489B (no) 1992-03-23
EP0284288B1 (en) 1992-05-27
FI881315A (fi) 1988-09-21
PT86975B (pt) 1992-06-30
IE60566B1 (en) 1994-07-27
CN88101424A (zh) 1988-10-05
ZA881515B (en) 1989-01-25
JP2859551B2 (ja) 1999-02-17

Similar Documents

Publication Publication Date Title
KR880011148A (ko) 레티노이드와 같은 작용성을 가지며 이종방향족 그룹과 이종이환식 그룹을 갖는 치환된 아세틸렌
KR880011068A (ko) 이종방향족 그룹과 테트랄린 그룹으로서 이중 치환되고 레티노이드와 같은 작용성을 갖는 아세틸렌
KR880011138A (ko) 레티노이드와 같은 작용성을 가지며 페닐그룹과 이종이환식 그룹으로 치환된 아세틸렌
KR880007411A (ko) 레티논산과 같은 작용을 갖는 에티닐헤테로 방향족-산류
DE69020060D1 (de) Phenylethenylverbindungen mit retenoidähnlicher Wirkung.
ES2079446T3 (es) Acetilenos disustituidos con un grupo heteroaromatico y un grupo cromanilo, tiocromanilo o 1,2,3,4-tetrahidroquinolinilo sustituido en posicion 2 que tienen actividad similar a retinoide.
KR880003893A (ko) 에티닐페닐을 함유하고 있는 레티오익산 유도체들

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20100930

Year of fee payment: 15

EXPY Expiration of term